Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Starling Oncology, Inc.TOI · Entity 5327 | Chief Financial Officer | May 21, 2026 | May 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Starling Oncology, Inc.
Report date May 21, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 414,801 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Other · Disposed 1,604 · Balance 414,801 F1: The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award made on May 21, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award made on May 21, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 22, 2026 21:32 UTC | Starling Oncology, Inc. TOI · Entity 5327 | OtherCommon Stock | 1,604 | $4.47 | $7,169.88 |
DisclosureSEC source: 0001079973-26-000723 · ownership.xml · nonDerivative · entry 1 Carter Robert Ross · CIK 0002039341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 414,801 F1 · kind: The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award made on May 21, 2024. Read SEC document |
| March 27, 2026 Filed Apr 2, 2026 00:47 UTC | Starling Oncology, Inc. TOI · Entity 5327 | OtherCommon Stock | 20,320 | $3.07 | $62,382.40 |
DisclosureSEC source: 0001079973-26-000440 · ownership.xml · nonDerivative · entry 2 Carter Robert Ross · CIK 0002039341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 416,405 F2 · shares: The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award on March 31, 2026 Read SEC document |
| March 27, 2026 Filed Apr 2, 2026 00:47 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 202,914 | $0.00 | $0.00 |
DisclosureSEC source: 0001079973-26-000440 · ownership.xml · nonDerivative · entry 1 Carter Robert Ross · CIK 0002039341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 436,725 F1 · shares: Represents RSU awards with 1/4 of the RSUs vesting on the first anniversary of the Vesting Commencement Date, with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 21:20 UTC | Starling Oncology, Inc. TOI · Entity 5327 | OtherCommon Stock | 1,314 | $3.59 | $4,717.26 |
DisclosureSEC source: 0001079973-26-000330 · ownership.xml · nonDerivative · entry 1 Carter Robert Ross · CIK 0002039341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 233,811 F1 · kind: The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award on March 17, 2026. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 22:04 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon Stock | 247 | $3.56 | $879.32 |
DisclosureSEC source: 0001079973-26-000008 · ownership.xml · nonDerivative · entry 1 Carter Robert Ross · CIK 0002039341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,122 F1 · kind: The reporting person used the proceeds of this sale to cover tax liabilities arising from the vesting of an RSU award on January 1, 2026. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:30 UTC Amendment | Starling Oncology, Inc. TOI · Entity 5327 | OtherCommon Stock | 244 | $3.67 | $895.48 |
DisclosureSEC source: 0001079973-26-000039 · ownership.xml · nonDerivative · entry 1 Carter Robert Ross · CIK 0002039341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,125 F1 · kind: The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award on January 1, 2026. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 23:00 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 195 | $0.00 | $0.00 |
DisclosureSEC source: 0001079973-25-001805 · ownership.xml · nonDerivative · entry 1 Carter Robert Ross · CIK 0002039341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,369 F1 · shares: Represents RSU awards that were fully vested upon grant, net of withholding tax obligations. Read SEC document |
| May 21, 2025 Filed May 22, 2025 18:12 UTC | Starling Oncology, Inc. TOI · Entity 5327 | Disposition to issuerClass A Common Stock | 1,601 | $2.68 | $4,282.68 |
DisclosureSEC source: 0001628280-25-027205 · wk-form4_1747937561.xml · nonDerivative · entry 1 Carter Robert Ross · CIK 0002039341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,174 F1 · shares: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:22 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantClass A Common Stock | 197,368 | $0.00 | $0.00 |
DisclosureSEC source: 0001799191-25-000021 · wk-form4_1743628960.xml · nonDerivative · entry 1 Carter Robert Ross · CIK 0002039341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,775 F1 · shares: Represents RSU awards with 1/4th of the RSUs vesting on the first anniversary of the Vesting Commencement Date, with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 21:27 UTC | Starling Oncology, Inc. TOI · Entity 5327 | PurchaseCommon Warrant · Derivative | 4,528 | $0.13 Strike: $1.20 | $566.00 |
DisclosureSEC source: 0001079973-25-000515 · ownership.xml · derivative · entry 2 Carter Robert Ross · CIK 0002039341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,528 Underlying: Common Stock · 4,528 shares Expires 2030-03-26 F1 · security: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit"). F1 · kind: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit"). F2 · kind: The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F3 · price: Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250. F4 · derivative.exercise_date: The reporting person may not exercise any portion of a Common Warrant to the extent that the reporting person would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately prior to or after giving effect to such exercise, as such percentage ownership is determined in accordance with Section 13(d) under the Exchange Act. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 21:27 UTC | Starling Oncology, Inc. TOI · Entity 5327 | PurchaseCommon Stock | 9,056 | $1.04 | $9,433.64 |
DisclosureSEC source: 0001079973-25-000515 · ownership.xml · nonDerivative · entry 1 Carter Robert Ross · CIK 0002039341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,407 F1 · kind: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit"). F2 · kind: The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F3 · price: Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250. Read SEC document |
| March 19, 2025 Filed Mar 20, 2025 21:56 UTC | Starling Oncology, Inc. TOI · Entity 5327 | Disposition to issuerClass A Common Stock | 1,150 | $0.89 | $1,022.35 |
DisclosureSEC source: 0001799191-25-000006 · wk-form4_1742507796.xml · nonDerivative · entry 1 Carter Robert Ross · CIK 0002039341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,351 F1 · shares: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 18:18 UTC | Starling Oncology, Inc. TOI · Entity 5327 | Disposition to issuerClass A Common Stock | 258 | $0.34 | $86.43 |
DisclosureSEC source: 0001799191-25-000002 · wk-form4_1736273886.xml · nonDerivative · entry 1 Carter Robert Ross · CIK 0002039341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,501 F1 · shares: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement. F2 · price: Price is the volume weighted average selling price of all sales by the Reporting Person on January 6, 2025 within a one-dollar range. Actual prices ranged from $0.293 to $0.335. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. Read SEC document |
| November 20, 2024 Filed Nov 21, 2024 23:21 UTC | Starling Oncology, Inc. TOI · Entity 5327 | Disposition to issuerClass A Common Stock | 235 | $0.14 | $31.96 |
DisclosureSEC source: 0001799191-24-000042 · wk-form4_1732231303.xml · nonDerivative · entry 1 Carter Robert Ross · CIK 0002039341 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,759 F1 · shares: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement. F2 · price: Price is the volume weighted average selling price of all sales by the Reporting Person on November 20, 2024 within a one-dollar range. Actual prices ranged from $0.136 to $0.168. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.